Misdiagnosed Myeloid Sarcoma of the Vulva

Yi He,Xudong Li,Ying Huang,Dongning Wang,Yuan Hu,Ruxun Huang

DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20121680

2013-01-01

Abstract:A 25-year-old woman presented with a lump in the vulva associated with progressive difficulty in urination that had persisted for approximately half a year. A diagnosis of Bartholin's abscess had been made in another hospital. Incision revealed no pus and ultrasonography showed a solid lesion in the left vulva. Partial excision of the tumor was implemented and histopathology showed a small round cell tumor. There were no other significant findings in her present or past medical history. She was admitted to our hospital with vulvar cancer. On gynecological examination, a 7 cm × 6 cm firm, hard, painless mass was found in the left labium majora. The right labium was inflamed but painless. Results of hematological investigations were mild anemia, with hemoglobin 84 g/L, red blood cell count 2.7×109/L, white blood cell count 6.53×109/L and platelet count 195×109/L. Magnetic resonance imaging revealed vulvar cancer with lymphadenopathy in the pelvic cavity. At our hospital, the initial pathohistological specimens were immediately re-examined. Analysis confirmed a diffusely infiltrating malignant neoplasm comprising intermediately sized round cells with uniform chromatin and small nucleoli (Figure 1). Paraffin-embedded sections were stained immunohistochemically. The tumor cells were positive for myeloperoxidase (MPO), CD34, CD15 and CD56 antibodies, and negative for CD20, CD79a, CD3, CD4, CD45RO and TdT monoclonal antibodies. CK, TIA1, GB, myogenin and EBER were also negative. When the pathological results were confirmed, a diagnosis of MS was made. We then performed bone marrow aspiration. The bone marrow smears showed 70% monoblasts, with Auer rods. On cytochemistry, the marrow was positive for peroxidase and α-naphthol butyrate esterase, and negative for naphthol AS-D chloroacetate esterase. Taking these results together, acute monoblastic leukemia (subtype M5) should be considered according to French-American-British (FAB) classification. However, immunophenotyping of bone marrow by flow cytometry (FCM) revealed CD45dim+, CD34+ blast cells expressing MPO, CD13, CD33, CD117, CD11b, CD56 and CD19, whereas the monocyte differentiation markers CD14, CD64, CD11b were absent. Cytogenetic studies of the marrow revealed the presence of 45,X,-X,t(8;21)(q22;q22). Dual fluorescence in situ hybridization (FISH) found the sample to be positive for the AML1/ETO gene. Given these data, a diagnosis of acute myeloid leukemia (AML) with t(8;21)(q22;q22) according to the WHO classification, and MS in the vulva was made. The patient was advised to undergo chemotherapy; however, she refused and was lost to follow-up.Figure 1.: Vulva biopsy shows infiltration of intermediate- sized round cells (HE staining, original magnification ×400).MS was first described in 1811 and originally called “chloroma” by King in 1853, involving one or more anatomical sites.1 The estimated incidence is 1.4% of patients with AML, and 1.1% of patients with AML or high-risk myelodysplastic syndrome (MDS).2 MS usually presents concomitantly with or after the onset of AML, the blastic phase of chronic myeloid leukemia or MDS. The diagnosis is often difficult when the myeloblastic cells are poorly differentiated and the symptoms are secondary to the mass effect of the tumor, and patients may be initially misdiagnosed with non-Hodgkin's lymphoma, a small round cell tumor or blastic plasmacytoid dendritic cell neoplasm. This patient presented with a vulvar lump that had caused diagnostic confusion before the diagnosis of underlying leukemia. The combination of histopathology and bone marrow examination provided an instructional tool for the diagnosis of MS. Once the diagnosis of MS is considered, immuno- histochemistry must play a role in its confirmation. As the myeloblasts in MS have an antigen profile similar to that of the blasts and precursor cells in AML, myeloid infiltration can be assessed using immunohistochemical stains to detect MPO, CD34, CD117 and lysozyme. In our case, CD34, MPO, CD15 and CD56 stained positive, which is consistent with MS. CD68/KP1, MPO, CD117, CD99, CD68/PG-M1,CD34, terminal-deoxy-nucleotidyl- transferase (TdT), CD56, CD61/linker for activation of T cells, CD30 and CD4 were frequent expressed marker. The combination of these markers can recognize the tumors with a more immature myeloid phenotype, as well as of cases with myelomonocytic, monoblastic, erythroid or megakaryocytic differentiation.3 MS is associated with chromosomal abnormalities including trisomy 8, trisomy 4, monosomy 7, 16q-, 5q-, 20q- and trisomy 11.4 Several chromosome rearrangements, especially t(8;21)(q22;q22) and, less often, inv(16)(p13;q22) were also seen. Both rearrangements involve the core binding factor gene and are associated with high rates of complete remission and long-term disease-free survival in AML. Our patient was considered as acute monoblastic leukemia according to the morphology and cytochemistry of bone marrow aspirates, but FCM found no CD14, CD64, CD11b expression, which are not consistent with acute monoblastic leukemia. Cytogenetic marrow studies revealed the presence of 45,X,-X,t(8;21)(q22;q22) and FISH found AML1/ETO to be positive; these are usually found in AML subtype M2 and less often in subtype M4 in the FAB classification. Recurrent chromosomal abnormalities are helpful in the diagnosis of leukemia and the classification of subtype. Thus, according to the WHO classification, the case should be diagnosed as AML with t(8;21)(q22;q22), and MS in the vulva. We described a patient with MS and a vulvar lump. This rare case was initially misdiagnosed because of the nonspecific clinical and histopathological findings. The combination of clinical history, histopathology, immunohistochemistry, bone marrow morphology, immunophenotyping and cytogenetics is essential for making the proper diagnosis.